Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
University of Pittsburgh Brain Health Initiative
NCT04708613
Recruiting
This project will define the prevalence of brain health (i.e., normal cognitive, neuromotor, behavioral function) in living professional football retirees and group-matched controls through a comprehensive assessment of clinical, neuroimaging, and biomarker measures.
Gender:
MALE
Ages:
Between 29 years and 59 years
Trial Updated:
06/12/2025
Locations: University of Pittsburgh Department of Neurosurgery, Pittsburgh, Pennsylvania
Conditions: Traumatic Brain Injury
Register for Updates
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798
Recruiting
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and seven substudies. Each substudy will enroll a different population of NSCLC participants. The goal of this umbrella master protocol is to screen potential participants with NSCLC for enrollment into 1 of 7 substudies. Participants mus... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
NCT04150497
Recruiting
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Gender:
ALL
Ages:
Between 15 years and 50 years
Trial Updated:
06/12/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/12/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Register for Updates
Combined Oral Contraceptive Pill and Resistance Starch
NCT06852365
Recruiting
This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
06/11/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Metabolic Syndrome, Polycystic Ovary Syndrome
Register for Updates
BCAAs in Concussion 2.0
NCT06829498
Recruiting
This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.
Gender:
ALL
Ages:
Between 11 years and 23 years
Trial Updated:
06/11/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Concussion, Brain, Concussion, Mild, Concussion
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Lewis Katz School of Medicine, Philadelphia, Pennsylvania
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
CGM for Management of Type 2 Diabetes in Pregnancy
NCT06628453
Recruiting
The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
06/11/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Type 2 Diabetes Mellitus (T2DM), Pregnancy
Register for Updates
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06508021
Recruiting
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO) * Whether andecalixim... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/11/2025
Locations: University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Fibrodysplasia Ossificans Progressiva
Register for Updates
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
NCT06439524
Recruiting
The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an FDA approved form of medical treatment for endometriosis. It is known to work in treating endometriosis pain. However, investigators do not know whether or not there is a benefit to beginning Rel-CT im... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Main Line Health, Wynnewood, Pennsylvania
Conditions: Endometriosis
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Penn State Health Medical Group - Andrews Patel, Harrisburg, Pennsylvania
Conditions: Breast Cancer
Register for Updates
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
NCT06137144
Recruiting
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
06/11/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Register for Updates